1. Home
  2. GSAT vs MIRM Comparison

GSAT vs MIRM Comparison

Compare GSAT & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GSAT
  • MIRM
  • Stock Information
  • Founded
  • GSAT 2003
  • MIRM 2018
  • Country
  • GSAT United States
  • MIRM United States
  • Employees
  • GSAT N/A
  • MIRM N/A
  • Industry
  • GSAT Telecommunications Equipment
  • MIRM Biotechnology: Pharmaceutical Preparations
  • Sector
  • GSAT Consumer Discretionary
  • MIRM Health Care
  • Exchange
  • GSAT Nasdaq
  • MIRM Nasdaq
  • Market Cap
  • GSAT 3.9B
  • MIRM 3.3B
  • IPO Year
  • GSAT 2006
  • MIRM 2019
  • Fundamental
  • Price
  • GSAT $43.44
  • MIRM $73.48
  • Analyst Decision
  • GSAT Strong Buy
  • MIRM Strong Buy
  • Analyst Count
  • GSAT 3
  • MIRM 11
  • Target Price
  • GSAT $43.33
  • MIRM $76.09
  • AVG Volume (30 Days)
  • GSAT 1.3M
  • MIRM 700.8K
  • Earning Date
  • GSAT 11-06-2025
  • MIRM 11-11-2025
  • Dividend Yield
  • GSAT N/A
  • MIRM N/A
  • EPS Growth
  • GSAT N/A
  • MIRM N/A
  • EPS
  • GSAT N/A
  • MIRM N/A
  • Revenue
  • GSAT $260,664,000.00
  • MIRM $429,161,000.00
  • Revenue This Year
  • GSAT $7.93
  • MIRM $53.14
  • Revenue Next Year
  • GSAT $11.32
  • MIRM $19.83
  • P/E Ratio
  • GSAT N/A
  • MIRM N/A
  • Revenue Growth
  • GSAT 14.85
  • MIRM 62.33
  • 52 Week Low
  • GSAT $15.00
  • MIRM $36.88
  • 52 Week High
  • GSAT $46.02
  • MIRM $78.10
  • Technical
  • Relative Strength Index (RSI)
  • GSAT 73.05
  • MIRM 54.95
  • Support Level
  • GSAT $35.39
  • MIRM $70.49
  • Resistance Level
  • GSAT $37.75
  • MIRM $74.96
  • Average True Range (ATR)
  • GSAT 2.01
  • MIRM 1.95
  • MACD
  • GSAT 0.75
  • MIRM -0.82
  • Stochastic Oscillator
  • GSAT 78.84
  • MIRM 43.98

About GSAT Globalstar Inc.

Globalstar Inc is a telecommunications company that derives revenue from the provision of mobile satellite services. Mobile satellite services are typically used by customers where existing terrestrial wireline and wireless communications networks are impaired or do not exist. The company provides communications services such as two-way voice and data transmission. In addition, one-way data transmission is also offered. Both services are offered using mobile or fixed devices. The company is an owner of satellite assets. It has one reportable segment: MSS business. The company generates the vast majority of its revenue within the United States.

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Share on Social Networks: